Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM3 | Q14832 | 2/20 | 0.68 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134136 | 0.92 | GRM3 (0.74) | GRM3FOLH1NAALAD2 | |
| SCHEMBL4135913 | 0.82 | GRM3 (1.00) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5134212 | 0.81 | FOLH1 (0.62) | GRM3FOLH1 | |
| SCHEMBL5060080 | 0.79 | GRM3 (0.85) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5060255 | 0.78 | GRM3 (0.82) | GRM3FOLH1NAALAD2 | |
| SCHEMBL17533535 | 0.78 | FOLH1 (0.65) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5053371 | 0.76 | GRM3 (0.79) | GRM3FOLH1NAALAD2 | |
| SCHEMBL1376163 | 0.76 | GRM3 (0.79) | GRM3FOLH1NAALAD2 | |
| SCHEMBL19225283 | 0.75 | FOLH1 (0.47) | GRM3FOLH1NAALAD2 | |
| Phosphoric Acid SCHEMBL27565979 | 0.75 | FOLH1 (0.83) | GRM3FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| US-6071965-A | TO INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY AND TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-06 | — | — | US | claimed |
| WO-1999033847-A9 | PHOSPHINIC ALKANOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 1999-09-23 | — | — | WO | claimed |
| WO-1999033847-A1 | PHOSPHINIC ALKANOIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| EP-1093453-B1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARM INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1571141-A2 | Naaladase inhibitors useful as pharmaceutical compounds and compositions | GUILFORD PHARMACEUTICALS INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6806261-B2 | CONTROL RELEASE TRANSFORMING GROWTH FACTOR; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIPROLIFERATIVE AGENT | GUILFORD PHARMACEUTICALS INC. | 2004-10-19 | — | — | US | disclosed |
| EP-1371367-A1 | Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases | GUILFORD PHARMACEUTICALS INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1140048-B1 | USE OF NAALADASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CERTAIN DISEASES | GUILFORD PHARM INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | JACKSON PAUL F (US) | 2003-05-01 | — | — | US | disclosed |
| US-20030017965-A1 | Methods for treating certain diseases using naaladase inhibitors | EISAI INC. | 2003-01-23 | — | — | US | disclosed |
| US-6228888-B1 | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1093453-A1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2001001974-A2 | NAALADASE INHIBITORS IN ANXIETY AND MEMORY DISORDERS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000038785-A2 | METHODS FOR TREATING CERTAIN DISEASES USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| US-6071965-A | TO INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY AND TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-06 | — | — | US | disclosed |
| WO-2000001668-A2 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999033847-A9 | PHOSPHINIC ALKANOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999033847-A1 | PHOSPHINIC ALKANOIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | GRM3 2045/4885FOLH1 1/4885NAALAD2 208/4885 |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | NAALAD2, DNPEP, NAAA | GRM3 305/4885FOLH1 22/4885NAALAD2 1/4885 |
| US-20030017965-A1 | Methods for treating certain diseases using naaladase inhibitors | NRDC, TGFB1, NAALAD2 | GRM3 3691/4885FOLH1 1103/4885NAALAD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.